Merck KGaA (MKGAF) to Release Earnings on Wednesday

Key Points

• Earnings due May 13: Merck KGaA is scheduled to report results Wednesday, May 13, with analysts expecting $2.27 EPS and $5.85 billion in revenue for the quarter.
• Stock and valuation: Shares opened at $131.64 and were down 0.8%; the company has a market capitalization of $17.01 billion, a P/E of 20.10, and a 52‑week range of $116.68–$159.34.
• Company profile: Merck KGaA is a German multinational chemical and pharmaceutical group founded in 1668, privately controlled by the Merck family and organized across three main business units serving global markets.

Merck KGaA (OTCMKTS:MKGAF - Get Free Report) is anticipated to post its resultson Wednesday, May 13th. Analysts expect Merck KGaA to post earnings of $2.27 per share and revenue of $5.8536 billion for the quarter.

Merck KGaA Stock Down 0.8%

Shares of Merck KGaA stock opened at $131.64 on Wednesday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.84 and a current ratio of 1.31. The stock has a market capitalization of $17.01 billion, a PE ratio of 20.10 and a beta of 0.96. Merck KGaA has a 52-week low of $116.68 and a 52-week high of $159.34. The company has a 50-day simple moving average of $133.46 and a two-hundred day simple moving average of $139.41.

About Merck KGaA

Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.

The company's operations are organized mainly into three businesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.